// App-Quantinova.ai

5022 : Final results of 2-dose fractionation of 177Lu-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Scott T. Tagawa

Principal Investigators

  • Jaspreet Batra

  • Shankar Vallabhajosula

  • Yuliya Jhanwar

  • Paul J. Christos

  • Lauren Emmerich

  • Beerinder S. Karir

  • Irene Karpenko

  • Linda Lam

  • Victor RA Febles

  • Ana M. Molina

  • Himisha Beltran

  • Stanley J. Goldsmith

  • Neil Harrison Bander

  • David M. Nanus

Medical Centers

  • Weill Cornell Medicine, New York, NY

  • Weill Cornell Medical College, New York, NY

  • New York-Presbyterian Hospital/Weill Cornell Medicine, New York, NY

  • NewYork-Presbyterian Hospital, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

  • Folate Hydrolase 1

Drug/Treatment

  • MLN591RL

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00538668

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved